1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1:

Baseline descriptives and MR imaging characteristics

CharacteristicsDataset A (n = 169)Dataset B, Placebo (n = 69)
Patient
    Female/male123:4650:19
    RRMS/SPMS with relapses169:057:12
    Mean age (SD)35.4 (8.4)38.5 (9.1)
    Mean disease duration in years (SD)6.4 (5.3)5.9 (5.9)
    Median baseline EDSS (IQR)2.0 (1.5–3.5)2.5 (1.5–3.5)
MR imaging
    % Inactive patients41.4%69.6%
    Mean number of enhancing lesions (SD)2.4 (4.1)1.3 (0.4)
  • Note:—EDSS indicates Expanded Disability Status Scale; IQR, interquartile range.